large b-cell lymphoma

As of January 2021, the Food and Drug Administration (FDA) has announced the approval of a new medication for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), the most common type of non-Hodgkin lymphoma, who are not eligible for autologous stem cell transplant. The new drug, called Monjuvi (tafasitimab) is a targeted therapy that will be used in combination with lenalidomide (Revlimid). Other combinations are currently under investigation.